GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Cyclically Adjusted FCF per Share

TECH (Bio-Techne) Cyclically Adjusted FCF per Share : $1.44 (As of Mar. 2025)


View and export this data going back to 1989. Start your Free Trial

What is Bio-Techne Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Bio-Techne's adjusted free cash flow per share for the three months ended in Mar. 2025 was $0.195. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.44 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Bio-Techne's average Cyclically Adjusted FCF Growth Rate was 3.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 9.40% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 7.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Bio-Techne was 38.70% per year. The lowest was 3.90% per year. And the median was 12.50% per year.

As of today (2025-06-17), Bio-Techne's current stock price is $51.63. Bio-Techne's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was $1.44. Bio-Techne's Cyclically Adjusted Price-to-FCF of today is 35.85.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Techne was 125.91. The lowest was 27.20. And the median was 53.38.


Bio-Techne Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Bio-Techne's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Cyclically Adjusted FCF per Share Chart

Bio-Techne Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.93 1.07 1.24 1.32 1.40

Bio-Techne Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.39 1.40 1.41 1.43 1.44

Competitive Comparison of Bio-Techne's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Bio-Techne's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bio-Techne's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Cyclically Adjusted Price-to-FCF falls into.


;
;

Bio-Techne Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bio-Techne's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.195/134.9266*134.9266
=0.195

Current CPI (Mar. 2025) = 134.9266.

Bio-Techne Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.202 100.684 0.271
201509 0.172 100.392 0.231
201512 0.226 99.792 0.306
201603 0.230 100.470 0.309
201606 0.225 101.688 0.299
201609 0.159 101.861 0.211
201612 0.259 101.863 0.343
201703 0.140 102.862 0.184
201706 0.300 103.349 0.392
201709 0.261 104.136 0.338
201712 0.217 104.011 0.281
201803 0.119 105.290 0.152
201806 0.384 106.317 0.487
201809 0.227 106.507 0.288
201812 0.271 105.998 0.345
201903 0.223 107.251 0.281
201906 0.283 108.070 0.353
201909 0.191 108.329 0.238
201912 0.353 108.420 0.439
202003 0.255 108.902 0.316
202006 0.173 108.767 0.215
202009 0.344 109.815 0.423
202012 0.483 109.897 0.593
202103 0.395 111.754 0.477
202106 0.675 114.631 0.795
202109 0.257 115.734 0.300
202112 0.551 117.630 0.632
202203 0.354 121.301 0.394
202206 0.545 125.017 0.588
202209 0.287 125.227 0.309
202212 0.360 125.222 0.388
202303 0.240 127.348 0.254
202306 0.448 128.729 0.470
202309 0.283 129.860 0.294
202312 0.426 129.419 0.444
202403 0.402 131.776 0.412
202406 0.358 132.554 0.364
202409 0.340 133.029 0.345
202412 0.483 133.157 0.489
202503 0.195 134.927 0.195

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Bio-Techne  (NAS:TECH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Bio-Techne's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=51.63/1.44
=35.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Bio-Techne was 125.91. The lowest was 27.20. And the median was 53.38.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Bio-Techne Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Bio-Techne Business Description

Industry
Traded in Other Exchanges
Address
614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
Executives
Kim Kelderman officer: Pres. Diagnostics & Genom 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Robert V Baumgartner director 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
John L Higgins director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Roeland Nusse director 473 TENNESSEE, PALO ALTO CA 94306
William Geist officer: PRESIDENT, PROTEIN SCIENCES 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth director, officer: Chief Executive Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow officer: SVP - General Counsel 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor officer: SVP Biotech 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel officer: Chief Financial Officer 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan director C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Julie L Bushman director 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Alpna Seth director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Randolph C Steer director 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413